Treatment for Inflammatory Arthritis

Initial Treatment Strategy

• The American College of Rheumatology recommends starting methotrexate immediately at 15 mg/week orally and rapidly escalating to 20-25 mg/week (or maximum tolerated dose) within 4-8 weeks 1, 4
• Methotrexate has the best efficacy/toxicity ratio among conventional DMARDs and serves as the anchor treatment 6
• Continue NSAIDs, analgesics, and/or glucocorticoids for symptomatic relief during DMARD initiation 1, 2, 5

Disease Activity Monitoring and Treatment Targets

• Measure disease activity every 3 months using SDAI (Simplified Disease Activity Index) or CDAI (Clinical Disease Activity Index) 1, 3
• Target remission (SDAI ≤3.3 or CDAI ≤2.8) or low disease activity (SDAI ≤11 or CDAI ≤10) 1, 4, 3

Treatment Escalation at 6-12 Months

• For moderate disease activity (SDAI 11-26), add sulfasalazine + hydroxychloroquine (triple therapy) or switch to subcutaneous methotrexate 1, 4
• For persistent moderate-to-high disease activity, add TNF inhibitor (adalimumab, etanercept) as first biologic option 1, 7
• The 2021 American College of Rheumatology guideline strongly supports this stepwise approach, with TNF inhibitors and abatacept as approved first-line biologics 7, 2

Special Populations

• For patients with pulmonary disease, methotrexate is conditionally recommended even with mild, stable lung disease, but inform patients of increased pneumonitis risk 2, 6
• For patients with heart failure (NYHA Class III-IV), use non-TNF biologics (abatacept, tocilizumab, rituximab) instead of TNF inhibitors 2, 6

Critical Timing Considerations

• Allow 3-6 months to fully assess efficacy of any new DMARD or biologic before switching 1, 4, 3
• Continuing NSAID monotherapy beyond 2 months in active arthritis is inappropriate 5

Common Pitfalls to Avoid

• Do not use inadequate methotrexate doses (<20 mg/week) before declaring failure 1, 4, 3
• Do not switch to oral methotrexate to subcutaneous route without first optimizing oral dosing 1, 4
• Do not abruptly discontinue DMARDs in patients at target; gradual discontinuation is preferred over abrupt cessation 2, 6